GSK news

GlaxoSmithKline completes acquisition of Stiefel

GlaxoSmithKline plc (GSK) today announced that it has completed its acquisition of Stiefel Laboratories, Inc.

Pandemic (H1N1) 2009 influenza update

GlaxoSmithKline (GSK) today issued an update on its progress to support governments and health authorities around the world respond to pandemic (H1N1) 2009 influenza.

GSK and Enigma Diagnostics Announce Commercial Partnership to Develop Point-of-Care Influenza Diagnostics

GlaxoSmithKline (GSK) and Enigma Diagnostics Limited today announced that they have signed worldwide agreements to develop and supply the first point-of-care diagnostic influenza tests to identify specific influenza virus strains using its real-time Polymerase Chain Reaction (PCR) technology platform, the Enigma ML (Mini Laboratory).

Human Genome Sciences and GlaxoSmithKline announce positive Phase 3 study results for Benlysta™ in systemic lupus erythematosus

Human Genome Sciences, Inc. and GSK today announced that Benlysta™ (belimumab, formerly LymphoStat-B®) met the primary endpoint in BLISS-52, the first of two pivotal Phase 3 trials in patients with serologically active systemic lupus erythematosus (SLE).

GSK announces new commitments to fight HIV/AIDS in Sub-Saharan Africa - special focus on care and treatment of children

Andrew Witty, Chief Executive Officer of GlaxoSmithKline, today announced a series of new initiatives targeted at improving research, development, and access to HIV/AIDS medicines for children in Sub-Saharan Africa and supporting healthcare for people living with HIV and AIDS.

WHO grants prequalification to Cervarix®: GSK’s vaccine to help combat cervical cancer in developing nations

The WHO decision is necessary for UN agencies and the GAVI Alliance to purchase the vaccine in partnership with developing countries and will help speed access to Cervarix globally.

Alnylam joins GSK in donating intellectual property to patent pool for neglected tropical diseases

GSK and Alnylam Pharmaceuticals, Inc. announced today that Alnylam will contribute more than 1500 issued or pending patents on its RNAi technology patent estate to the patent pool established by GSK earlier this year.

Landmark study for GSK’s cervical cancer vaccine published in The Lancet

Largest efficacy trial of a cervical cancer vaccine showed Cervarix® protects against the five most common cancer-causing virus types

GSK further extends its product portfolio in the Middle East and North Africa

GSK today announced that it has acquired the branded generics business of Bristol Myers Squibb (BMS) in Lebanon, Jordan, Syria, Libya and Yemen for a cash consideration of $23.2m (£14.2m).

Seretide: Irish patent litigation update

GlaxoSmithKline (GSK) today announced that the Commercial Court in Dublin, Ireland, ruled in patent litigation regarding GSK’s product Seretide, an inhaled respiratory treatment for asthma and COPD.

Syndicate content